← back to search

Langdon L. Miller

Clinical Solutions ·
Area of research
Molecular Biology · Genetics
Research interest
Research interests include Cancer therapeutics and mechanisms, Chronic Lymphocytic Leukemia Research, Lymphoma Diagnosis and Treatment, and Lung Cancer Research Studies.
h-index
35
citations
14,125
works
79
NIH funding
primary concept
Medicine
email

Recent publications

ROR1 targeting with the antibody-drug conjugate VLS-101 is effective in Richter syndrome patient–derived xenograft mouse models
Blood 2021cited by 88position: middledoi
Zilovertamab Vedotin Targeting of ROR1 as Therapy for Lymphoid Cancers
NEJM Evidence 2021cited by 75position: middledoi
A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia
Blood 2015cited by 240position: middledoi
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
New England Journal of Medicine 2014cited by 1,682position: middledoi
PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
New England Journal of Medicine 2014cited by 1,062position: middledoi
Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia
Blood 2014cited by 584position: middledoi
Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma
Blood 2014cited by 209position: middledoi
Combinations of the Selective Phosphatidylinositol 3-Kinase-Delta (PI3Kdelta) Inhibitor GS–1101 (CAL-101) with Rituximab and/or Bendamustine Are Tolerable and Highly Active in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL): Results From a Phase I Study
Blood 2012cited by 36position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Ian W. Flinn · Centennial Medical Center5 papers (2012–2015)Richard R. Furman · Cornell University5 papers (2012–2021)Nina D. Wagner‐Johnston · Washington University in St. Louis4 papers (2012–2014)Steven Coutré · Stanford University4 papers (2012–2015)Brian J. Lannutti · Fate Therapeutics (United States)4 papers (2012–2021)Leanne Holes · Gilead Sciences (United States)3 papers (2012–2015)Stephen E. Spurgeon · National Institute of Oncology3 papers (2014–2021)Albert S. Yu · Gilead Sciences (United States)3 papers (2014–2015)David M. Johnson · Gilead Sciences (United States)3 papers (2014–2021)Brad S. Kahl · New York University3 papers (2014–2014)Sven de Vos · APLA Health3 papers (2012–2021)Don M. Benson · The Ohio State University2 papers (2014–2014)John C. Byrd · The University of Texas Southwestern Medical Center2 papers (2014–2014)Jennifer R. Brown · Harvard University2 papers (2014–2014)Wayne R. Godfrey · Therapeutics Clinical Research2 papers (2014–2014)Thomas J. Kipps · Moores Cancer Center2 papers (2015–2021)John P. Leonard · NYU Langone Health2 papers (2012–2014)Roger Dansey · Merck & Co., Inc., Rahway, NJ, USA (United States)2 papers (2014–2015)Katti Jessen · Fate Therapeutics (United States)2 papers (2021–2021)Heather K. Webb · Gilead Sciences (United States)2 papers (2014–2014)